Company profile
Ticker
KYTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
831365441
KYTX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
26 Mar 24
8-K
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
26 Mar 24
SEC STAFF
SEC staff action: Order
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Feb 24
S-8
Registration of securities for employees
8 Feb 24
424B4
Prospectus supplement with pricing info
8 Feb 24
CERT
Certification of approval for exchange listing
8 Feb 24
EFFECT
Notice of effectiveness
8 Feb 24
S-1/A
IPO registration (amended)
6 Feb 24
8-A12B
Registration of securities on exchange
5 Feb 24
Latest ownership filings
SC 13G
Northpond Ventures III, LP
22 Feb 24
SC 13G
GILEAD SCIENCES, INC.
20 Feb 24
4
Change in insider ownership
14 Feb 24
4
Fred E Cohen
14 Feb 24
4
BETH C SEIDENBERG
14 Feb 24
4
Sean E Harper
14 Feb 24
4
Change in insider ownership
14 Feb 24
SC 13G
Bain Capital Life Sciences Opportunities III, LP
14 Feb 24
4
Change in insider ownership
13 Feb 24
4
Michael P. Rubin
12 Feb 24
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 24 | Northpond Ventures III GP | Common Stock | Buy | Acquire P | Yes | No | 22 | 450,000 | 9.90 mm | 450,000 |
12 Feb 24 | Northpond Ventures III GP | Common Stock | Conversion | Acquire C | Yes | No | 0 | 2,805,426 | 0.00 | 2,805,426 |
12 Feb 24 | Northpond Ventures III GP | Series B Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 12,767,776 | 0.00 | 0 |
12 Feb 24 | Gilead Sciences | Common Stock | Buy | Acquire P | No | No | 22 | 910,000 | 20.02 mm | 4,126,119 |
12 Feb 24 | Gilead Sciences | Common Stock | Conversion | Acquire C | No | No | 0 | 3,216,119 | 0.00 | 3,216,119 |
12 Feb 24 | Gilead Sciences | Series B Convertible Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 7,746,139 | 0.00 | 0 |
12 Feb 24 | Gilead Sciences | Series A-2 Convertible Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 6,890,744 | 0.00 | 0 |
12 Feb 24 | Westlake BioPartners Fund I | Common Stock | Conversion | Acquire C | Yes | No | 0 | 735,984 | 0.00 | 735,984 |
12 Feb 24 | Westlake BioPartners Fund I | Common Stock | Conversion | Acquire C | Yes | No | 0 | 3,787,940 | 0.00 | 3,787,940 |
12 Feb 24 | Westlake BioPartners Fund I | Series B Redeemable Convertible Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 3,349,538 | 0.00 | 0 |
News
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
1 Apr 24
Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
26 Mar 24
Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
8 Mar 24
JP Morgan Initiates Coverage On Kyverna Therapeutics with Overweight Rating, Announces Price Target of $39
4 Mar 24
Press releases
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
11 Apr 24
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
29 Mar 24
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
26 Mar 24
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
7 Mar 24
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
12 Feb 24